The treatment options for liver fibrosis include blocking the TGF-β/mothers against the decapentaplegic homolog 2 and 3 (SMAD 2/3) signaling pathway and focusing on HSC activation. This evidence concerns the gene SMAD2 and Hepatic fibrosis.